Related by context. All words. (Click for frequent words.) 76 phase IIa clinical 76 Phase Ib clinical 75 randomized Phase IIb 75 multicenter clinical 75 placebo controlled Phase III 74 multicenter placebo controlled 73 placebo controlled Phase 73 double blinded randomized 73 placebo controlled randomized 73 multicenter randomized controlled 73 randomized clinical 73 Phase IIIb clinical 72 RE LY ® 72 randomized Phase III 72 prospective randomized controlled 72 prospective multicenter 72 phase IIb clinical 72 randomized controlled clinical 72 Phase 1b clinical 72 Phase 2a clinical 72 phase IIIb 72 phase IIa 72 multicenter prospective 72 double blinded placebo 71 multicenter randomized placebo controlled 71 randomized placebo controlled 71 placebo controlled 71 blinded randomized placebo controlled 71 randomized controlled 71 multicentre randomized 71 randomized blinded 71 ONTARGET 71 riociguat 71 Phase IIIb 71 placebo controlled clinical trials 71 multicenter randomized clinical 71 Phase IIB 71 blinded placebo controlled 71 landmark ATHENA 70 Phase 1a clinical 70 active comparator 70 phase Ib 70 multicenter randomized 70 phase IIb trial 70 Intervention Effectiveness 70 nonrandomized 70 desvenlafaxine succinate 70 Phase IIb clinical 70 Phase 1b trial 70 Phase 2b study 70 multicenter Phase II 70 phase IIb 70 Phase III randomized 70 bicifadine 70 Phase 2a trial 70 VADT 70 dose escalation Phase 70 sunitinib malate 70 placebo controlled studies 70 Phase III placebo controlled 70 BRIM2 70 phase 2a 70 GAMMAGARD 70 multicenter 70 BRIM3 70 ROCKET AF 70 controlled multicenter 69 Phase IIa clinical 69 Phase 2b trial 69 confirmatory clinical 69 dose escalation clinical 69 Traficet EN 69 alvespimycin 69 masked placebo controlled 69 randomized multicenter 69 pertuzumab 69 ADVANCE PD 69 Phase 2b clinical 69 confirmatory Phase III 69 LUX Lung 69 TMC# C# 69 CAMMS# 69 STRIDE PD 69 EchoCRT 69 prospective randomized placebo 69 Phase Ib 69 sorafenib Nexavar 69 CIMZIA ™ 68 subanalysis 68 DAPT 68 prospective multicenter randomized 68 Carotid Revascularization Endarterectomy vs. 68 Safinamide 68 MEND CABG 68 PD LID 68 multicenter randomized double 68 blind randomized placebo 68 Phase Ib II 68 RE LY 68 relapsed MM 68 ToGA 68 SPIRIT FIRST 68 Phase IIb trial 68 EDEMA3 68 teriflunomide 68 APEX PD 68 prospective randomized 68 evaluating tivozanib 68 viral kinetic 68 placebo controlled trials 68 multicenter Phase 68 dose escalation trial 68 BR.# 68 HCV SPRINT 68 Phase III randomized controlled 68 RSD# oral 68 MERLIN TIMI 68 APTIVUS r 68 axitinib 68 ECASS 68 CIMZIA TM certolizumab pegol 68 relapsing multiple sclerosis 68 MGd 68 phase IIb study 68 recurrent malignant glioma 68 enzastaurin 68 Phase III clinical 68 tocilizumab 68 Clinical Antipsychotic Trials 68 diabetic neuropathic pain 68 ENESTnd 68 ABSORB trial 68 vidofludimus 68 tanespimycin 68 Phase #b/#a 68 multicentre randomized double 68 Aflibercept 68 randomized multicenter trial 68 AZILECT R 68 prospective randomized multicenter 68 Betaferon ® 68 multicentre 68 ACTEMRA 68 dosing cohorts 67 CARE HF 67 thorough QT 67 oral deforolimus 67 phase III ACCLAIM 67 ADAGIO study 67 LUMINATE 67 blinded randomized 67 blind multicenter 67 reslizumab 67 Phase IIIb study 67 dirucotide MBP# 67 randomized multicentre 67 PFO migraine 67 Phase IIa trial 67 CYPHER R Sirolimus eluting 67 CATIE AD 67 oral rivaroxaban 67 Phase IIa trials 67 Phase IIa 67 ibandronate 67 analgesic efficacy 67 EVEREST II 67 SPIRIT IV 67 prospective observational 67 INCB# [001] 67 AIR CF1 67 double blind placebo 67 HCV RESPOND 2 67 label dose escalation 67 CHAMPION PCI 67 forodesine 67 dosage regimens 67 registrational Phase 67 safinamide 67 elotuzumab 67 DU #b 67 Randomized controlled 67 trastuzumab emtansine T DM1 67 AVERROES 67 dose dose escalation 67 dose escalation phase 67 Ophena 67 SPIRIT III 67 Ophena TM 67 ENDEAVOR IV 67 Phase #b/#a clinical 67 velafermin 67 ENDEAVOR II 67 Phase 1b 67 NO# [002] 67 NSABP B 67 TAXUS ATLAS 67 ataluren 67 multicenter multinational 67 refractory CLL 67 dexpramipexole 67 phase Ib clinical 67 RRMS patients 67 HuMax EGFr 67 nab paclitaxel 67 Tolvaptan 67 davunetide intranasal AL 67 TAXUS VI 67 CIMZIA TM 67 Phase 2b kidney transplant 67 Phase Ib study 67 Pimavanserin 67 TAXUS IV 67 Phase 2a 67 Amrubicin 67 pharmacokinetic PK study 66 randomized controlled clinical trials 66 recurrent glioblastoma multiforme 66 clinical trial 66 SNT MC# 66 ACAPODENE 66 ARCOXIA 66 TG MV 66 dose escalation study 66 ruboxistaurin 66 ascending dose 66 symptomatic BPH 66 NLX P# 66 brivaracetam 66 ATACAND 66 pharmacokinetics PK 66 opioid induced bowel dysfunction 66 substudy 66 Zenvia Phase III 66 galiximab 66 ExTRACT TIMI 66 iniparib 66 blind randomized controlled 66 MIST II 66 multicenter phase 66 CALGB 66 GOUT 66 noninferiority 66 ongoing Phase 1b 66 tolvaptan 66 Phase IIA 66 Dacogen injection 66 canakinumab 66 Catena ® 66 Acute Ischemic Stroke 66 Phase Ib IIa 66 HGS# 66 Tarceva TM 66 EOquin TM 66 oral ridaforolimus 66 PRoFESS 66 Androxal TM 66 randomized Phase 2b 66 EURIDIS 66 cortical stimulation 66 lomitapide 66 RezularTM 66 NCCTG 66 RoACTEMRA 66 afatinib 66 AIR CF2 66 Multicenter 66 rALLy clinical trial 66 prospectively defined 66 HORIZONS AMI trial 66 lacosamide 66 APTIVUS 66 cilostazol 66 Zemplar Capsules 66 ACCORD Lipid 66 preclinical efficacy 66 Phase III VISTA 66 Phase IIb III 66 multicenter Phase III 66 dosing cohort 66 PRIMO CABG 66 PSMA ADC 66 ZACTIMA 66 pharmacokinetic PK 66 oral FTY# 66 YONDELIS 66 visilizumab 66 multicenter trials 66 HPTN 66 fosbretabulin 66 Phase #/#a 66 Edge STudy 66 ACTEMRA TM 66 evaluating REVLIMID 66 BRAF inhibitor 66 blind randomized 66 deforolimus 66 OHR/AVR# 66 dyskinesia PD LID 66 neratinib 66 SUTENT 66 paclitaxel eluting stents 66 edoxaban 66 evaluating mipomersen 65 KRN# 65 Microplasmin 65 bosentan 65 clinical pharmacology studies 65 CALGB # [002] 65 DASISION 65 randomized controlled multicenter 65 PROactive study 65 CBLC# 65 Phase IIb trials 65 everolimus eluting stents 65 blind placebo 65 NEVO ™ 65 randomized multicenter Phase III 65 cannabinor 65 ZYBRESTAT fosbretabulin 65 Phase III 65 JAK inhibitor 65 PERSEUS 65 Phase IIb 65 AGILECT R 65 INCB# [003] 65 SCH # 65 REMINYL ® 65 mycophenolate mofetil 65 randomized controlled trial 65 PRECiSE 65 Azedra 65 Degarelix 65 CYPHER Stent 65 PREZISTA r 65 multicentre randomized controlled 65 assessing T DM1 65 Phase 2b 65 trials RCTs 65 morphometric vertebral fractures 65 cariprazine 65 BARI 2D 65 ZOLINZA 65 Prestara 65 NATRECOR R 65 CANCIDAS 65 DDP# 65 placebo controlled dose escalation 65 MIRAPEX 65 Sorafenib HCC Assessment 65 ProSavin 65 Plicera 65 Phase IIb clinical trials 65 arzoxifene 65 Tyrima 65 IBS C 65 ORENCIA ® 65 dose escalation 65 CLARITY TIMI 65 Val HeFT 65 prucalopride 65 MIRCERA 65 posaconazole 65 Sym# 65 pivotal bioequivalence 65 GetGoal Phase III 65 AEGR 65 COPAXONE R 65 APEX AMI trial 65 Acute Decompensated Heart Failure 65 EXPLORE Xa 65 HF ACTION 65 CUSTOM II 65 PRE SURGE 65 relapsed myeloma 65 venlafaxine XR 65 dexanabinol 65 AeroLEF TM 65 Stenting Trial CREST 65 MAGE A3 ASCI 65 SYMMETRY trial 65 Torisel 65 LibiGel Phase III 65 recurrent NSCLC 65 icatibant 65 apremilast 65 Multicenter Automatic Defibrillator Implantation 65 metastatic HRPC 65 pain palliation 65 eosinophilic asthma 65 Phase III psoriasis 65 Zoraxel 65 BOLDER II 65 multicenter study 65 NP2 Enkephalin 65 TRANSFORMS 65 MoxDuo IR 65 somatostatin analog 65 deferiprone 65 pharmacodynamic profile 64 CA4P 64 Phase 1a 64 AZOR 64 Raptiva ® 64 FOLPI 64 Initiated Phase 64 alemtuzumab Campath 64 tolerability pharmacokinetics 64 Pivotal Phase III 64 ENDEAVOR III 64 pregabalin Lyrica 64 mapatumumab 64 clevidipine 64 prospective nonrandomized 64 VELCADE melphalan 64 doxorubicin docetaxel 64 CLARITY study 64 CUSTOM III 64 relapsing MS 64 abiraterone acetate 64 NEVO RES 64 label multicenter 64 Randomised 64 pomalidomide 64 DEB# 64 AIR2 Trial 64 ancrod 64 SUTENT ® 64 Capesaris 64 secondary efficacy endpoints 64 dose regimens 64 treatment naive genotype 64 APPRAISE 64 randomized controlled Phase 64 intravenous dosing 64 bendamustine 64 teduglutide 64 XIENCE V Stent System 64 efficacy endpoint 64 BCIRG 64 Combo Stent 64 trastuzumab Herceptin ® 64 PROMACTA 64 AIM HIGH 64 relapsed refractory multiple myeloma 64 glatiramer acetate 64 palonosetron 64 Subgroup analysis 64 pivotal Phase III 64 Octreolin 64 Diabetic Macular Edema 64 ILLUMINATE 64 Orazol 64 Placebo controlled 64 cilengitide 64 mg administered orally 64 ABSORB clinical 64 pharmacodynamic PD 64 ularitide 64 Quinamed 64 rFVIIa 64 Phase III pivotal 64 huN# DM1 64 REALITY Trial 64 Phase Ib clinical trials 64 HORIZONS AMI 64 Bezielle 64 CRLX# 64 docetaxel Taxotere ® 64 subgroup analyzes 64 Sibutramine Cardiovascular Outcomes 64 AVOREN 64 decitabine 64 Tanespimycin 64 Symadex 64 Randomized Evaluation 64 Phase III confirmatory 64 knee osteoarthritis OA 64 neurologic progression 64 gemcitabine carboplatin 64 PEGINTRON TM 64 selective androgen receptor modulator 64 desvenlafaxine 64 TAXUS V 64 varespladib 64 ritonavir boosted 64 RLAI 64 Long Lesion 64 ADMIRE HF 64 tapentadol ER 64 TACI Ig 64 Edwards SAPIEN valve 64 fallopian tube cancers 64 dabigatran etexilate 64 gefitinib Iressa 64 PRX # 64 Phase 1b clinical trials 64 relapsing remitting MS RRMS 64 AGILECT ® 64 Glypromate 64 Randomized Double blind 64 STX# 64 Xanafide 64 Imprime PGG 64 randomized trials 64 randomized double 64 nonmetastatic prostate cancer 64 recurrent glioma 64 Phase III metastatic melanoma 64 telcagepant 64 NATRECOR ® 64 prospective multicenter study 64 ASTEROID 64 RhuDex 64 SCD HeFT 64 randomized 64 CYPHER ® Sirolimus eluting 64 Zenvia ™ 64 Pivotal Clinical Trial 64 COMFORT II 64 NGX# 64 EDEMA3 trial 64 blind placebo controlled 64 Intervention Effectiveness CATIE 64 metreleptin 64 Teriflunomide 64 Tavocept 64 mertansine 64 ganetespib 64 adalimumab 64 MADIT II 64 Randomized Phase 64 Denufosol 64 neoadjuvant 64 pharmacodynamic effects 64 orally inhaled migraine 64 Phase #b/#a trial 64 dose cohorts 64 mg/m2 cohort 64 Elagolix 64 goserelin 64 Ozarelix 64 vorinostat 64 Pivotal Trial 64 receptor tyrosine kinase inhibitor 64 PRADAXA 64 dose cohort 64 relapsing remitting multiple sclerosis 64 painful diabetic neuropathy 64 HeFT 64 ascending doses 64 Gabapentin GR 64 Cloretazine 64 IPLEX 64 GSK# [001] 64 Durezol 64 XGEVA 64 paclitaxel poliglumex 64 Phase Ia 64 Ceplene/IL-2 63 trial evaluating PRX# 63 TASKi3 63 depsipeptide 63 phase IIb III 63 VITAL Trial 63 schizophrenia CIAS 63 recurrent GBM 63 ACZ# 63 Pirfenidone 63 intermittent dosing 63 budesonide foam 63 Trandolapril 63 cediranib 63 ACTIVE W 63 Lu AA# 63 serotonin norepinephrine reuptake inhibitor 63 anti arrhythmic drug 63 REVIVE Diabetes 63 Neurodex 63 elagolix 63 Golimumab 63 carotid endarterectomy CEA 63 single ascending dose 63 ACRIN 63 Prostate Cancer Prevention 63 NEVO 63 VA# [002] 63 interferon gamma 1b 63 rilonacept 63 sorafenib tablets 63 CCX# B 63 Vidaza azacitidine 63 ACUITY trial 63 ELACYT 63 Dasatinib 63 pegylated liposomal doxorubicin 63 INSPIRE Trial Phase III 63 Afatinib 63 MabCampath 63 salmeterol fluticasone 63 plasma kallikrein inhibitor 63 blinded randomized controlled 63 FASLODEX 63 Phase 2b clinical trials 63 PXD# 63 Multaq R 63 CYPHER ® Stent 63 Prostate Lung Colorectal 63 comparator arm 63 Tocilizumab 63 MabThera rituximab 63 evaluable subjects 63 atherothrombotic events 63 risperidone Risperdal 63 EXPAREL ™ 63 platelet inhibitor 63 longitudinal cohort study 63 TLK# 63 inhibitor RG# 63 tezampanel 63 SIMPADICO 63 PRIMO CABG2 63 metastatic hormone refractory 63 KRAS mutations occur 63 Prospective Randomized 63 vicriviroc 63 alvimopan 63 lintuzumab 63 KAPIDEX 63 plus prednisone 63 laquinimod 63 investigational protease inhibitor 63 cinacalcet 63 paricalcitol 63 Tasimelteon 63 Phase III Pivotal 63 CCX# 63 methylnaltrexone 63 gadobutrol 63 Gattex 63 viral kinetics 63 TEMSO 63 BENICAR HCT 63 rosuvastatin Crestor 63 noninfectious uveitis 63 acute coronary syndromes ACS 63 Hepatocellular Carcinoma HCC 63 prospective multicentre 63 R#/MEM # 63 prospective longitudinal 63 Doxil ® 63 R#/MEM 63 Archexin 63 Randomized Double Blind 63 Myocardial Infarction Study 63 irbesartan 63 ONTARGET R 63 acyclovir Lauriad R 63 Ocrelizumab 63 ASCEND HF 63 Phase III Clinical Trials 63 MIRAPEX ER 63 Cimzia ® certolizumab pegol 63 LEVADEX 63 telaprevir dosing 63 unblinding 63 TYKERB 63 catheter occlusion 63 briakinumab 63 PRT# 63 ANCHOR trial 63 Phenoptin 63 pioglitazone HCl 63 RAPAFLO R 63 NeuroStar TMS Therapy 63 PARTNER Trial 63 baminercept 63 interferon beta 1b 63 temsirolimus 63 octreotide LAR 63 TDF FTC 63 eplerenone 63 induced macular edema 63 bardoxolone methyl 63 denufosol 63 ARIXTRA 63 OPT CHF 63 CIPN 63 SNT-MC#/idebenone 63 chronic myocardial ischemia 63 TORISEL 63 secondary efficacy endpoint 63 XmAb# 63 vismodegib 63 Dose escalation 63 tipranavir 63 aldosterone antagonists 63 PreCISe 63 PSN# [002] 63 PEGylated interferon beta 1a 63 Onrigin 63 Aryplase 63 headache nasopharyngitis 63 Enzastaurin 63 registrational 63 GEM OS2 63 bazedoxifene 63 Dextofisopam 63 abatacept 63 boosted protease inhibitor 63 prospectively randomized 63 tarenflurbil 63 FAME Study 63 primary hypercholesterolemia 63 lurasidone 63 senicapoc 63 MACUGEN 63 eltrombopag 63 regorafenib 63 randomized discontinuation 63 azacitidine 63 Mipomersen 63 pazopanib 63 retinal vein occlusion induced 63 trodusquemine 63 cathepsin K inhibitor 63 acute ischemic stroke 63 efficacy tolerability 63 GW# [003] 63 Corlux 63 invasive candidiasis 63 TTF Therapy 63 eculizumab 63 PHX# 63 ischemic cardiomyopathy 63 relapsed AML 63 Digital Mammographic Imaging 63 registrational trial 63 IIa trial 63 candesartan cilexetil 63 CTAP# Capsules 63 epoetin alpha 63 ORACLE MS 63 AA Amyloidosis 63 achieved statistical significance 63 maximally tolerated dose 63 INTERCEPT platelets 63 Hyphanox 63 Deforolimus 63 rufinamide 63 randomized clinical trials 63 MEND CABG II 63 Allovectin 7 ® 63 opioid naive 63 OncoVEX GM CSF 63 dextofisopam 63 Dapagliflozin 63 MoxDuo TM IR 63 rasagiline 62 XL# SAR# 62 HBeAg negative patients 62 AVADO 62 LEXIVA r 62 Overactive Bladder OAB 62 OvaRex ® MAb 62 huC# DM4 62 ixabepilone 62 TELCYTA 62 Vernakalant 62 alemtuzumab treated 62 fluvastatin 62 satraplatin Phase 62 virologic response 62 olaparib 62 VIRAMUNE XR 62 CHARM Added 62 pyridostigmine 62 Vandetanib 62 protease inhibitor PI 62 tesmilifene 62 trabedersen 62 lupus nephritis 62 novel oral anticoagulant 62 Dacogen decitabine 62 OLYMPIA registry 62 concurrent chemoradiation 62 ascending dose study 62 symptomatic VTE 62 clinically meaningful efficacy 62 Anturol TM 62 dosing regimens 62 evaluating Actimmune 62 Amplimexon 62 azilsartan medoxomil 62 Tamibarotene 62 multicentre study 62 SABCS 62 SUCCEED trial 62 modified REGENESIS Phase IIb 62 Spine Patient Outcomes 62 Phase III trials 62 intravitreal injection 62 pramipexole 62 retrospective cohort 62 weekly subcutaneous injections 62 eszopiclone 62 anakinra 62 antiepileptic drug 62 Alequel 62 TG# [003] 62 NSABP 62 cobiprostone 62 tolerability 62 crizotinib PF # 62 clobazam 62 plus dexamethasone 62 PRTX 62 lenalidomide dexamethasone 62 REMICADE ® 62 Multiple Ascending Dose 62 Cimzia TM 62 Perforomist Inhalation Solution 62 Phase III multicenter 62 ALGRX 62 EFAPROXYN 62 Raloxifene Evaluation MORE 62 SYNTAX trial 62 mg kg dose 62 IL# PE#QQR 62 tenofovir emtricitabine 62 Prostate AdenoCarcinoma Treatment 62 subcutaneous methylnaltrexone 62 II Clinical Trial 62 LCP AtorFen 62 randomized discontinuation trial 62 LHON 62 fostamatinib 62 Aggressive Reduction 62 Phase #/#a clinical 62 PREVENT IV 62 confirmatory Phase 3 62 PFO closure 62 dacetuzumab 62 bazedoxifene conjugated estrogens 62 chlorambucil 62 rosuvastatin #mg 62 Plecanatide 62 stage IIIB 62 Ereska 62 Clonicel 62 recurrent glioblastoma 62 bevacizumab Avastin ® 62 Prosaptide 62 antihypertensive therapy 62 Darusentan 62 thromboembolic events 62 chemoradiotherapy 62 everolimus eluting stent 62 #mg BID [001] 62 FOLOTYN ® 62 postmenopausal osteoporotic women 62 entinostat 62 lapatinib Tykerb 62 LHRH antagonists 62 perampanel 62 Cloretazine R VNP#M 62 Fibrillex TM 62 randomized #:#:# 62 NVA# 62 iPrEx study 62 antiarrhythmic drug 62 diarrhea predominant irritable 62 class mGluR5 inhibitor 62 MADIT CRT 62 Xelox 62 EQUIP OB 62 ORENCIA R 62 treatment naïve genotype 62 label dose titration 62 ozarelix 62 Zarnestra 62 eritoran 62 ziprasidone Geodon 62 BNC# 62 Zolinza 62 clinicaltrials 62 synthetic retinoid 62 blind multicentre 62 RG# [001] 62 Randomized Study 62 Pemetrexed 62 peg interferon 62 elacytarabine 62 atrasentan 62 placebo controlled multicenter 62 Phase III Clinical Trial 62 hyperphenylalaninemia HPA due 62 cetrorelix 62 Oral NKTR 62 Renal Cell Carcinoma RCC 62 carboplatin paclitaxel 62 HuLuc# 62 RE MODEL 62 PREOS 62 hereditary antithrombin deficiency 62 CRVO 62 oral diclofenac 62 AEG# 62 HER2 positive metastatic breast 62 XIENCE V PROMUS Stent 62 oral prodrug 62 Daclizumab 62 subcutaneously administered 62 aflibercept 62 romidepsin 62 albiglutide 62 Triolex 62 LY# [003] 62 CLORETAZINE TM VNP#M 62 Ixempra 62 intravenous methylnaltrexone 62 rosuvastatin 62 FOLFOX6 chemotherapy regimen 62 acute mania 62 ABC/3TC 62 MYCAMINE 62 ENDEAVOR clinical 62 EVIZON 62 ThermoDox R 62 patients undergoing percutaneous 62 CLL8 62 TRITON TIMI 62 docetaxel chemotherapy 62 recurrent metastatic 62 basal bolus regimen 62 #mg/day [001] 62 favorable tolerability 62 PF # [002] 62 low dose cytarabine 62 PRECISE 62 TAXUS Liberte Stent 62 rALLy trial 62 KNS # 62 bosutinib 62 virus HCV protease inhibitor 62 QTc 62 Phase III HEAT 62 multicenter clinical trials 62 TNF alpha inhibitor 62 donepezil Aricept 62 HOPE TOO 62 ximelagatran 62 AVONEX ® 62 NCCTG N# 62 LEUKINE 62 ACOMPLIA R 62 ruxolitinib 62 eluting stent 62 TOLAMBA 62 refractory gout 62 tiotropium 62 NOX E# 62 Sprycel dasatinib 62 PAOD 62 paliperidone ER 62 bortezomib Velcade 62 BAY #-# 62 Natalizumab 62 adjuvant endocrine therapy 62 sulodexide 62 MADIT 62 rivaroxaban Xarelto 62 Hsp# Inhibitor 62 neoadjuvant treatment 62 tecarfarin 62 bexarotene 62 mycophenolate mofetil MMF 62 Cholesterol Levels SPARCL 62 COU AA 62 LIALDA 62 glufosfamide 62 rt PA 62 Oral Fingolimod 62 DermaVir Patch 62 relapsed ALL 62 MoxDuo 62 CERVARIX 62 RAPTIVA 62 HCD# [002] 62 XIENCE V demonstrated 62 ELONVA 62 Chronic Heart Failure 62 ziconotide 62 atacicept 62 paliperidone palmitate 62 lumiliximab 62 safety tolerability pharmacokinetic 62 GRN# 62 recurrent herpes labialis 62 Cloretazine ®